Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

Key Takeaways J&J is grappling with Stelara biosimilar setbacks, Medicare changes and ongoing talc litigation.Stelara sales fell sharply in 2025 amid biosimilar launches and Medicare Part D redesign impacts.J&J projects stronger 2026 growth driven by key drugs, new launches and improving MedTech momentum.Johnson & Johnson (JNJ) faces several challenges, like potential losses from expiring drug patents, ongoing legal battles related to its talc powder and broader macroeconomic uncertainties. Here, we discuss ...